Home › Amgen Submits BLA for Investigational BiTEA Immunotherapy Blinatumomab
 

Keywords :   


Amgen Submits BLA for Investigational BiTEA Immunotherapy Blinatumomab

2014-09-23 07:04:12| Biotech - Topix.net

THOUSAND OAKS, Calif., Sept. 22, 2014 /PRNewswire/ -- Amgen today announced submission of a Biologics License Application to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager antibody construct, blinatumomab.

Tags: bla submits investigational immunotherapy

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.09Labelexpo Americas highlights, Maxcess announces acquisition and more
20.09September Cattle on Feed as expected
20.09USDA announces major investment in meat and poultry processing
20.09Atlantic Tropical Weather Outlook
20.09Eastern North Pacific Tropical Weather Outlook
20.09This weeks lesson: Weaning matters in the cattle market
20.09Construction giant collapses putting 2,400 jobs at risk
20.09KANSAI HELIOS Further Expands as System Supplier in Italy
More »